Demographics
| Demographics (n = 106) | |||
|---|---|---|---|
|
Median (range) age, y Age ≥75 y, n (%) |
63.5 (31–84) 12 (11) |
Renal function (CrCl), n (%) ≥ 60 mL/min < 60 mL/min |
60 (57) 46 (43) |
|
ISS staging, n (%) I II III |
26 (25) 40 (38) 40 (38) |
ECOG Score 0 1 2 |
29 (27) 69 (65) 8 (8) |
| Median (range) time since diagnosis, y | 4.8 (1-24) |
Cytogenetics profile* t (4; 14) del17p del13q amp1q21 Other |
9 (10) 16 (17) 30 (32) 23 (24) 43 (45) |
Abbreviations: CrCl, creatinine clearance; ISS, International Staging System
*Cytogenetic abnormalities were detected by fluorescence in-situ hybridization or karyotyping, or both at baseline (n=95).
Prior Therapies
| Prior therapies (n = 106) | |||
|---|---|---|---|
| Median (range) number of prior therapies | 5 (2–14) | > 3 lines of prior therapy, n ( 0/o) | 87 (82) |
|
Prior chemotherapy, n (%) Alkylating agents Anthracyclines |
106 (100) 106 (100) 55 (52) |
Prior IMiD, n (%) LEN POM THAL |
106 (100) 105 (99) 67 (63) 47 (44) |
| Prior ASCT, n (%) | 85 (80) |
Prior PI, n (%) BORT CARF |
106 (100) 105 (99) 53 (50) |
Abbreviations: ASCT, autologous stem cell transplantation; BORT, bortezomib; CARF, carfilzomib; LEN, lenalidomide;
POM, pomalidomide; THAL, thalidomide.
Refractory Status
- Patients were heavily pretreated, and most patients were refractory to multiple lines of PI and IMiD treatment
| Refractory to | n (%) |
|---|---|
| PI and IMiD | 101 (95) |
| Last prior therapy | 103 (97) |
| BORT | 95 (90) |
| CARF | 51 (48) |
| LEN | 93 (88) |
| POM | 67 (63) |
| THAL | 29 (27) |
| Alkylating agent | 82 (77) |
| BORT + LEN | 87 (82) |
| BORT + LEN + CARF | 42 (40) |
| BORT + LEN + POM | 57 (54) |
| BORT + LEN + CARF + POM | 33 (31) |
Abbreviations: BORT, bortezomib; CARF, carfilzomib; LEN, lenalidomide; POM, pomalidomide; THAL, thalidomide
